1h Free Analyst Time
The heparin market is forecast to grow by $3.00 billion from 2023-2027, accelerating at a CAGR of 6.94% during the forecast period.Speak directly to the analyst to clarify any post sales queries you may have.
The market is driven by the increasing prevalence of coagulation disorders, the increasing prevalence of chronic conditions, and the reintroduction of alternative sources to produce heparin. This study identifies the increasing R&D activities and new therapeutic applications of heparin as another prime reason driving the heparin market growth during the next few years. Also, the advent of biosimilar low-molecular-weight heparin and the development of drugs to remove heparin after surgery will lead to sizable demand in the market.
The report on the heparin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment.
The heparin market is segmented as below:
By Product
- Low-molecular-weight heparin
- Others
By Route of Administration
- Subcutaneous injection
- Intravenous/infusion
By Geographical Landscape
- Europe
- North America
- Asia
- Rest of World (ROW)
The report on the heparin market covers the following areas:
- Heparin market sizing
- Heparin market forecast
- Heparin market industry analysis
A robust vendor analysis within the report is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading heparin market vendors that include Aspen Pharmacare Holdings, B. Braun SE, Baxter International Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Opocrin SpA, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Shenzhen Techdow Pharmaceutical, Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Also, the heparin market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The analyst recognizes the following companies as the key players in the global heparin market: Aspen Pharmacare Holdings, B. Braun SE, Baxter International Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Opocrin SpA, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Shenzhen Techdow Pharmaceutical, Teva Pharmaceutical Industries Ltd., and Viatris Inc.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing R&D activities and new therapeutic applications of heparin.'
According to the report, one of the major drivers for this market is the increasing prevalence of coagulation disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aspen Pharmacare Holdings Ltd
- B.Braun SE
- Baxter International Inc.
- Dr Reddys Laboratories Ltd.
- Eisai Co. Ltd.
- Fresenius SE and Co. KGaA
- Hebei Changshan Biochemical
- Hikma Pharmaceuticals Plc
- Laboratorios Farmaceuticos ROVI S A
- LEO Pharma AS
- Nanjing Kingfriend Biochemical
- Nichi Iko Pharmaceutical Co. Ltd.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Shanghai Fosun Pharmaceutical Group Co. Ltd.
- Shenzhen Techdow Pharmaceutical
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Opocrin SpA
